Ultrasound-on-Chip Licensing Market to Reach USD 200.5 Million by 2036 as AI-Enabled Imaging and Embedded Ultrasound Technologies Drive Healthcare Innovation

Future Market Insights forecasts the global Ultrasound-on-Chip Licensing market to grow from USD 50.0M in 2026 to USD 200.5M by 2036 (14.9% CAGR), implying an absolute USD 150.5M opportunity over 2026–2036. Growth is attributed to rising handheld/portable ultrasound adoption, expanding AI-assisted diagnostics, and increased semiconductor licensing partnerships, with Butterfly Embedded leading at a 61.0% share (2026) and Medical holding a 72.0% share. The report highlights China as the fastest-growing country at a 16.8% CAGR through 2036, but it is market-research/forecasting news rather than a company-specific catalyst.

Analysis

This is more a validation event than a near-term earnings catalyst. For BFLY, the relevant mechanism is not addressable market size; it’s whether licensing can turn a low-margin hardware story into higher-quality recurring software/IP revenue with less working capital intensity. If that transition is real, the market should eventually award a higher multiple, but only after we see evidence of OEM conversions, design wins, and royalty-like cash flow rather than slideware.

The competitive implication is that value in portable imaging is drifting up the stack: semiconductor IP, workflow software, and regulatory/clinical integration become the moat, while transducer-heavy OEMs risk commoditization. That’s mildly constructive for BFLY and potentially mixed for GEHC/large incumbents if they’re forced to defend margins through bundling or acquisition. Semiconductor suppliers with imaging content can also pick up incremental design-in volume, but the revenue pool is still too small to matter for larger caps in the next few quarters.

The market is likely overrating the immediacy of the opportunity. These programs usually face long qualification cycles, IP-friction, and reimbursement/regulatory gating, so the first real check is 1-3 quarters of partner announcements and gross margin mix, not this report. The contrarian read is that the report may be a useful sentiment tailwind for BFLY, but the economic impact is probably immaterial unless management can show that licensing scales faster than hardware sales and at materially higher incremental margins.

Key Decisions for Investors

• BFLY: tactical long on a 1-3 month horizon only if management confirms incremental OEM design wins or backlog conversion; otherwise fade any headline-driven pop. Risk/reward is attractive only if the stock is still pricing BFLY as a pure hardware story.
• BFLY vs GEHC pair: modest long BFLY / short GEHC as a relative-value expression on IP monetization versus mature imaging distribution, but keep sizing small because the fundamental delta is more narrative than financial in the near term.
• Do not chase GEHC or large-cap medtech on this theme; the report is too small to move estimates, and any benefit is likely offset by competitive pressure and faster-follow bundling. Use GEHC only as a hedge against a BFLY-specific execution miss.
• Set an alert for BFLY gross margin and other revenue over the next 2 quarters: if licensing does not show up as higher-quality revenue or if cash burn stays unchanged, the thesis is falsified and the multiple re-rating should be sold.
• Watch semiconductor/input-name beneficiaries only if they disclose imaging-specific design wins; absent that, treat ON and similar names as secondary beneficiaries with no standalone trade.